Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients

• Conditions: Kidney Transplantation

• Registration Number: NCT00903578
• Lead Sponsor: Ramathibodi Hospital

Brief Summary

The present study will examine whether serum FGF-23 and serum phosphate at baseline of kidney transplant recipients can predict progression of allograft dysfunction at 3 years and all-cause mortality at 5 years.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-05
• Study First Submitted: 2009-05-01
• Study First Submitted QC: 2009-05-15
• Study First Posted: 2009-05-18
• Status Verified: 2009-12
• Last Update Submitted: 2009-12-16
• Last Update Posted: 2009-12-17
• Primary Completion: 2015-01
• Study Completion: 2015-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• at least one year post-transplantation
• no more than 10% increase in serum creatinine for the past 3 months

Exclusion Criteria

• refuse to participate in the study
• any acute illnesses

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression of allograft dysfunction and all-cause Mortality	3 and 5 years

Secondary Outcome Measures

Name	Time	Method
Relationship of FGF-23 and 25-OH-D, 1-25-OH-D, PTH, calcium, phosphate, urine phosphate and eGFR	1 year

Trial Locations

Locations (1)

Ramathibodi Hospital, Mahidol University; 🇹🇭 Phayathai, Bangkok, Thailand